← FDA DRUG APPROVALS

FDA NDA · NDA218710

VOQUEZNA

Sponsor: PHATHOM PHARMACEUTICALS INC

APPLICATION
NDA218710
TYPE
NDA
ORIGINAL APPROVAL
2024-07-17
LATEST ACTION
2024-07-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

VOQUEZNAPrescription
VONOPRAZAN FUMARATE EQ 10MG BASE · TABLET · ORAL
VOQUEZNAPrescription
VONOPRAZAN FUMARATE EQ 20MG BASE · TABLET · ORAL

Approval history

2024-07-17Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →